摘要
背景:目前,课题中认知障碍者对肌肉减少症所知甚少。本研究的目的是首先说明在不同阶段的认知障碍肌症减少症的患病率,其次检查在男性和女性的认知障碍者中肌肉减少症相关因素。方法:418例门诊患者(正常认知;数控:35,遗忘型轻度认知损害;aMCI:40,阿尔茨海默病;AD:343)从2014年10月至2014年6月参加在日本国家老年医学和老年医学中心的记忆诊所。本实验评估了认知状况、活力、心情抑郁、身体质量指数、握力、定时和测试、骨骼肌质量和血清25-羟维生素D水平、白蛋白和肌酐。肌肉减少症被定义为由肌肉功能低(物理性能低或低肌肉力量和肌肉质量低)和肌肉质量差共同引起。我们进行单因素和多因素Logistic回归分析来探讨与肌肉减少症的相关因素。结果:肌肉减少症的总患病率为21.1%(NC = 8.6%, aMCI = 12.5%, AD = 23.3%)。在两性中,与肌肉减少症的相关因素有:年龄(P<0.01),身体质量指数(P<0.001)和活力(P<0.05)。在女性中,25-羟维生素D血清水平与肌肉减少症有关(P<0.05)。结论:低活力可能是引起老年痴呆者患肌肉减少症的一个特异性风险因素。认知功能障碍患者对肌肉减少症的预防应该是从物理和心理问题进行探讨。
关键词: 25 -羟基维生素D ,阿尔茨海默病,遗忘型轻度认知功能障碍 ,认知能力下降,肌肉减少症,活力
Current Alzheimer Research
Title:Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Volume: 13 Issue: 6
Author(s): Taiki Sugimoto, Rei Ono, Shunsuke Murata, Naoki Saji, Yasumoto Matsui, Shunpei Niida, Kenji Toba, Takashi Sakurai
Affiliation:
关键词: 25 -羟基维生素D ,阿尔茨海默病,遗忘型轻度认知功能障碍 ,认知能力下降,肌肉减少症,活力
摘要: Background: To date, very little is known about the nature of sarcopenia in subjects with cognitive impairment. The aims of this study were firstly to clarify the prevalence of sarcopenia at various stages of cognitive impairment, and secondly to examine factors related to sarcopenia in men and women with cognitive impairment. Method: The subjects were 418 outpatients (normal cognition; NC: 35, amnestic mild cognitive impairment; aMCI: 40, Alzheimer disease; AD: 343) who attended the Memory Clinic at the National Center for Geriatrics and Gerontology of Japan during the period from October 2010 to July 2014. Cognitive status, vitality, depressive mood, body mass index, hand grip strength, timed up and go test, skeletal muscle mass and serum levels of 25-hydroxyvitamin D, albumin and creatinine were assessed. Sarcopenia was defined as the presence of both poor muscle function (low physical performance or low muscle strength) and low muscle mass. We performed the univariate and multivariate logistic regression analyses to explore factors associated with sarcopenia. Results: The overall prevalence of sarcopenia was 21.1% (NC = 8.6%, aMCI = 12.5%, AD = 23.3%). In both sexes, factors associated with sarcopenia were age (P < .01), body mass index (P < .001) and vitality (P < .05). In women, serum level of 25-hydroxyvitamin D was associated with sarcopenia (P < .05). Conclusion: Low vitality could be a dementia-specific risk factor for sarcopenia. Prevention of sarcopenia in patients with cognitive impairment should be approached from physical and psychologic points of view.
Export Options
About this article
Cite this article as:
Taiki Sugimoto, Rei Ono, Shunsuke Murata, Naoki Saji, Yasumoto Matsui, Shunpei Niida, Kenji Toba, Takashi Sakurai , Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease., Current Alzheimer Research 2016; 13 (6) . https://dx.doi.org/10.2174/1567205013666160211124828
DOI https://dx.doi.org/10.2174/1567205013666160211124828 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medical Music Therapy Based on Baby Science (Baby-Science-Based Music Therapy) and Assistive Technology for Children
Current Pediatric Reviews A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry ADF/Cofilin-Actin Rods in Neurodegenerative Diseases
Current Alzheimer Research Neuroprotective Mechanisms as Treatment Strategy in Alzheimers disease
Current Medicinal Chemistry - Central Nervous System Agents Protein Conformational Diseases: From Mechanisms to Drug Designs
Current Drug Discovery Technologies Blood Coagulation and the Risk of Atherothrombosis
Current Genomics Editorial: Current Vision of Systemic Autoimmune Diseases - From Diagnosis to Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mild Cognitive Impairment (MCI) - The Novel Trend of Targeting Alzheimers Disease in Its Early Stages - Methodological Considerations
Current Alzheimer Research Editorial (Thematic Issue: “Infectious Diseases in Asia-Pacific: Historical and Contemporary Perspectives”)
Infectious Disorders - Drug Targets Nose to Brain Drug Delivery System: A Comprehensive Review
Drug Delivery Letters Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer’s Disease
Current Neurovascular Research A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics <i>Nigella sativa</i> L., Supplementary Plant with Anticholinesterase Effect for Cognition Problems: A Kinetic Study
Current Aging Science Memorization Test and Resting State EEG Components in Mild and Subjective Cognitive Impairment
Current Alzheimer Research PDE-5 Inhibitors: Clinical Points
Current Drug Targets